Phase I Clinical Trial of Personalized Dendritic Cell Injection ZSNeo-DC1.1 in the Treatment of Recurrent or Progressive High-grade Glioma
Latest Information Update: 19 Feb 2025
At a glance
- Drugs Dendritic cell cancer vaccine ZhongSheng BioTech (Primary)
- Indications Glioma
- Focus Adverse reactions
Most Recent Events
- 11 Feb 2025 Planned End Date changed from 4 Feb 2025 to 31 Dec 2025.
- 11 Feb 2025 Planned primary completion date changed from 24 Dec 2024 to 30 Jun 2025.
- 19 Feb 2024 New trial record